Pzena Investment Management LLC Reduces Stock Holdings in USANA Health Sciences, Inc. $USNA

Pzena Investment Management LLC lessened its position in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 2.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,108,933 shares of the company’s stock after selling 25,496 shares during the quarter. Pzena Investment Management LLC owned approximately 6.01% of USANA Health Sciences worth $19,373,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in USNA. Inspire Investing LLC raised its position in USANA Health Sciences by 22.6% during the first quarter. Inspire Investing LLC now owns 29,362 shares of the company’s stock worth $513,000 after acquiring an additional 5,419 shares during the last quarter. Hsbc Holdings PLC raised its position in shares of USANA Health Sciences by 72.8% during the 4th quarter. Hsbc Holdings PLC now owns 13,334 shares of the company’s stock worth $259,000 after purchasing an additional 5,617 shares during the last quarter. State of Tennessee Department of Treasury lifted its stake in USANA Health Sciences by 307.8% in the 4th quarter. State of Tennessee Department of Treasury now owns 29,290 shares of the company’s stock valued at $636,000 after buying an additional 22,108 shares in the last quarter. Empowered Funds LLC lifted its stake in USANA Health Sciences by 10.6% in the 4th quarter. Empowered Funds LLC now owns 60,437 shares of the company’s stock valued at $1,186,000 after buying an additional 5,782 shares in the last quarter. Finally, Tudor Investment Corp ET AL grew its holdings in USANA Health Sciences by 354.8% during the 4th quarter. Tudor Investment Corp ET AL now owns 109,686 shares of the company’s stock valued at $2,153,000 after buying an additional 85,570 shares during the last quarter. 54.25% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on USNA. Wall Street Zen raised USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Saturday, June 20th. Zacks Research cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, USANA Health Sciences has an average rating of “Reduce”.

USANA Health Sciences Price Performance

Shares of USNA stock opened at $21.49 on Friday. The firm has a market cap of $396.79 million, a P/E ratio of 45.73, a PEG ratio of 0.85 and a beta of 0.73. USANA Health Sciences, Inc. has a 1-year low of $16.60 and a 1-year high of $38.32. The firm’s 50-day simple moving average is $19.04 and its 200-day simple moving average is $19.43.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.17. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. The firm had revenue of $250.22 million during the quarter, compared to the consensus estimate of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Analysts expect that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current fiscal year.

Insider Transactions at USANA Health Sciences

In other USANA Health Sciences news, Director John Turman Fleming sold 2,450 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $17.93, for a total transaction of $43,928.50. Following the completion of the sale, the director owned 4,230 shares of the company’s stock, valued at approximately $75,843.90. The trade was a 36.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Brent Neidig sold 5,002 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total value of $97,288.90. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 17,660 shares of company stock valued at $336,579. Corporate insiders own 0.82% of the company’s stock.

USANA Health Sciences Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.